Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 19/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 14/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 11/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 8/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.46 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2199790 | 1.00 | SLC6A4 (0.46) | SLC6A4SLC6A2CYP2D6SLC6A3KCNH2 | |
| SCHEMBL2204531 | 1.00 | SLC6A4 (0.46) | SLC6A4SLC6A2CYP2D6SLC6A3KCNH2 | |
| SCHEMBL5762640 | 0.90 | SLC6A4 (0.41) | SLC6A4SLC6A2CYP2D6SLC6A3KCNH2 | |
| SCHEMBL2675101 | 0.90 | PIK3CD (0.41) | SLC6A4SLC6A2CYP2D6SLC6A3KCNH2 | |
| SCHEMBL30675011 | 0.85 | PIK3CD (0.41) | SLC6A4SLC6A2CYP2D6SLC6A3KCNH2 | |
| SCHEMBL3833561 | 0.85 | SLC6A4 (0.37) | SLC6A4SLC6A2CYP2D6SLC6A3KCNH2 | |
| SCHEMBL13567753 | 0.85 | SLC6A4 (0.37) | SLC6A4SLC6A2CYP2D6SLC6A3KCNH2 | |
| SCHEMBL3832520 | 0.85 | SLC6A4 (0.37) | SLC6A4SLC6A2CYP2D6SLC6A3KCNH2 | |
| SCHEMBL2674426 | 0.82 | PIK3CD (0.34) | SLC6A4SLC6A2CYP2D6SLC6A3KCNH2 | |
| SCHEMBL17284676 | 0.82 | PIK3CD (0.34) | SLC6A4SLC6A2CYP2D6SLC6A3KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8754107-B2 | Aminopyrrolidines as chemokine receptor antagonists | ABBVIE INC. (US) | 2014-06-17 | — | — | US | disclosed |
| US-7977358-B2 | Pyrazol derivatives | HOFFMANN-LA ROCHE INC. (US) | 2011-07-12 | — | — | US | disclosed |
| EP-2182953-A2 | NEW PYRAZOL DERIVATIVES | F. Hoffmann-Roche AG (CH) | 2010-05-12 | — | — | EP | disclosed |
| US-20090029963-A1 | PYRAZOL DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-01-29 | — | — | US | disclosed |
| WO-2009013211-A2 | NEW PYRAZOL DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-01-29 | — | — | WO | disclosed |
| US-20080176883-A1 | Antiinflammtory, antiproliferative, anticancer agents; (3-Hydroxy-pyrrolidin-1-yl)-(3-trifluoromethyl-7,8-dihydro-5H-[1,6]naphthyridin-6-yl)-methanone | ABBVIE INC. | 2008-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176883-A1 | Antiinflammtory, antiproliferative, anticancer agents; (3-Hydroxy-pyrrolidin-1-yl)-(3-trifluoromethyl-7,8-dihydro-5H-[1,6]naphthyridin-6-yl)-methanone | MIF, CCL5, CCR2 | SLC6A4 3027/4885SLC6A2 3761/4885CYP2D6 519/4885 |
| US-20090029963-A1 | PYRAZOL DERIVATIVES | CCR1, CCR3, CCRL2 | SLC6A4 3118/4885SLC6A2 4180/4885CYP2D6 1221/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.